Compugen (CGEN)
(Delayed Data from NSDQ)
$1.75 USD
+0.03 (1.74%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.74 -0.01 (-0.57%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CGEN 1.75 +0.03(1.74%)
Will CGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CGEN
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
uniQure (QURE) Soars on New Huntington's Disease Study Data
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Other News for CGEN
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Earns Milestone from AstraZeneca Trial
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to receive $5M milestone payment from AstraZeneca
Biotech Alert: Searches spiking for these stocks today